|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 伊立替康+卡铂或口服伊托泊苷+卡铂治疗广泛期小细胞肺癌的随机临床Ⅲ期对照研究显示文摘研究背景:顺铂联合伊托泊苷(EP方案)是目前小细胞肺癌的标准治疗方案,但广泛期小细胞肺癌的预后极差,即使总体健康状况良好的患者完成EC方案治疗后中位生存期仅约10个月。一项旨在研究伊立替康联合顺铂(即IP方案)对照EP方案疗效的Ⅲ期临床研究结果显示,接受IP方案者的中位生存期达12.8个月,优于接受EP方案治疗者的9.4个月(P=0.002)。 | Hermes A Bergman B Bremnes R 陆嘉德 | 2009 | 中国癌症杂志2009，19，2： | 9 |
| 2 | Circulating DNA is a useful prognostic factor in patients with adranced nou-small cell lung cancer显示文摘 | Sirera R Bremnes RM Cabrera A | 2011 | J Thorac Oncol2011，6，2： | 1 |
| 3 | Circulating DNA is a useful prognostic factor in patients with adrancednou small cell lung cancer 显示文摘 | Sirera R Bremnes RM Cabrera A | 2011 | J Thorac Oncol2011，6，2： | 1 |
| 4 | Hight-throughput tissue microarray used to the E-cadherin pathway in non-small-cell lung cancer显示文摘 | Bremnes RM Veve R Gabrielson E | 2002 | J Clin Oncol2002，20，10： | 1 |
| 5 | Irinotecan plus Carboplatin versus oral Etoposide plus Carboplatin in extensive small-cell lung cancer: A randomized phase Ⅲ trial 显示文摘 | Hermes A Bergman B Bremnes R | 2008 | J Clin Oncol2008，26，26： | 1 |
| 6 | The role of tumopinfihra- ring immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis:emphasis on non-small cell lung cancer显示文摘 | Bremnes R M A1 Shibli K Donnem T | 2011 | J Thorac Oncoh2011，6，4： | 1 |
| 7 | High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer显示文摘 | BREMNES R M VEVE R GABRIELSON E | 2002 | J Clin Oncol2002，20，： | 1 |
| 8 | High through put tissue microarray analysis used to evaluate biology and prognostic signif- icance of the E-cadherin pathway in non-small cell lung cancer 显示文摘 | Bremnes RM Veve R Gabrielson E | 2002 | J Clin Onco12002，20，10： | 1 |
| 9 | Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer:a randomised trial by the Norwegian Lung Cancer Study Group显示文摘 | Strm H H Bremnes R M Sundstrm S H | 2013 | Br J Cancer2013，109，6： | 1 |
| 10 | Phase Ⅲ study by the Norwegian lung cancer study group:pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced Non-small-cell lung cancer显示文摘 | Gronberg B H Bremnes R M Flatten O | 2009 | Journal of Clinical Oncology2009，27，19： | 1 |
| 11 | The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and lung cancer invasion, metastasis, and prognosis 显示文摘 | Bremnes RM Veve R Hirsch FR | 2002 | Lung Cancer2002，36，： | 1 |
| 12 | Irinotecan plus carboplatin venus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase Ⅲ trial显示文摘 | Hermes A Bergman B Bremnes R | 2008 | J Clin Oncol2008，26，26： | 1 |
| 13 | High throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small cell lung caneer显示文摘 | Bremnes RM Veve R Gabrielson E | 2002 | J Clin Oneol2002，20，10： | 1 |
| 14 | Pilomatrixcarcimo with multiple metastasis:report of a case and reviewof literature显示文摘 | Bremns R M Kvamme J M Stalsberg H | 1999 | Eur J Cancer1999，35，3： | 1 |
| 15 | Irinotecan plus carbopla- tin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase m trial 显示文摘 | Hermes A Bergman B Bremnes R | 2008 | J Clin Oncol2008，26，26： | 1 |
| 16 | Angiogenesis in non-small cell lung cancer:the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood显示文摘 | Bremnes RM Camps C Sirera R | 2006 | Lung Cancer2006，51，2： | 1 |
| 17 | Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer:a randomized phase Ⅲ trial显示文摘 | Hermes A Bergman B Bremnes R | 2008 | J Clin Oncol2008，26，26： | 1 |
| 18 | High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non– small-cell lung cancer显示文摘 | Bremnes RM Veve R Gabrielson E | 2002 | J Clin Oncol2002，20，10： | 1 |
| 19 | Analysis of c - kit expression in small cell lung cancer: prevalence and prog- nostic implications 显示文摘 | Camps C Sirera R Bremnes RM | 2006 | Lung Cancer2006，52，3： | 1 |
| 20 | Irinotecan plus car boplatin versus oral etoposide plus earboplatin in extensive small-cell lung cancer: a randomized phase III trial显示文摘 | Hermes A Bergman B Bremnes R | 2008 | J Clin Oncol2008，26，26： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员